TNXP (Tonix Pharmaceuticals Holding) EV-to-Revenue : 8.04 (As of May. 25, 2025)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Tonix Pharmaceuticals Holding's enterprise value is $80.75 Mil. Tonix Pharmaceuticals Holding's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $10.04 Mil. Therefore, Tonix Pharmaceuticals Holding's EV-to-Revenue for today is 8.04.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's EV-to-Revenue or its related term are showing as below:

TNXP' s EV-to-Revenue Range Over the Past 10 Years
Min: -5.57 Med: 0.58 Max: 9.62
Current: 8.04

During the past 13 years, the highest EV-to-Revenue of Tonix Pharmaceuticals Holding was 9.62. The lowest was -5.57. And the median was 0.58.

TNXP's EV-to-Revenue is ranked worse than
52.56% of 995 companies
in the Biotechnology industry
Industry Median: 7.17 vs TNXP: 8.04

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-25), Tonix Pharmaceuticals Holding's stock price is $28.93. Tonix Pharmaceuticals Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $59.40. Therefore, Tonix Pharmaceuticals Holding's PS Ratio for today is 0.49.

Tonix Pharmaceuticals Holding EV-to-Revenue Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding EV-to-Revenue Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

1.04

5.35

Tonix Pharmaceuticals Holding Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															1.61	0.96	0.32	5.35	-0.82

Competitive Comparison of Tonix Pharmaceuticals Holding's EV-to-Revenue

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Tonix Pharmaceuticals Holding EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tonix Pharmaceuticals Holding's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	80.750	/	10.041
	=	8.04

Tonix Pharmaceuticals Holding's current Enterprise Value is $80.75 Mil.
Tonix Pharmaceuticals Holding's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.04 Mil.

Tonix Pharmaceuticals Holding (NAS:TNXP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tonix Pharmaceuticals Holding's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	28.93	/	59.397
	=	0.49

Tonix Pharmaceuticals Holding's share price for today is $28.93.
Tonix Pharmaceuticals Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.40.

Tonix Pharmaceuticals Holding EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304